Actively Recruiting
Nasopharyngeal Carriage of S. Pneumoniae
Led by Association Clinique Thérapeutique Infantile du val de Marne · Updated on 2026-03-19
25760
Participants Needed
1
Research Sites
1320 weeks
Total Duration
On this page
Sponsors
A
Association Clinique Thérapeutique Infantile du val de Marne
Lead Sponsor
P
Pfizer
Collaborating Sponsor
AI-Summary
What this Trial Is About
This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae serotypes in children with acute otitis media and modified the resistance of this bacterial species to antibiotics.
CONDITIONS
Official Title
Nasopharyngeal Carriage of S. Pneumoniae
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children of both sexes
- Children with suppurative acute otitis media aged 6 to 36 months
- Healthy children aged 6 months to 15 years
- Informed consent obtained from parents or guardians
- Children who have not received antibiotic treatment within 7 days before enrollment
You will not qualify if you...
- Children with severe underlying diseases
- Children included in the study during the previous 12 months
- Children with bullous myringitis cannot be included
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
ACTIV
Créteil, France
Actively Recruiting
Research Team
C
Corinne Levy, MD
CONTACT
S
Stéphane Béchet, MsC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here